 |
|
|
| |
Development of Potent Novel Oral Pan-genotypic HCV Nucleotide,
NS5A, NS5B Non-nucleoside, and Helicase Inhibitors
|
| |
| |
Reported by Jules Levin
HEP DART 2015, December 6-10, 2015, Wailea, Hawaii
Douglas L. Mayers, MD
AASLD: Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C- (11/23/15)
|
| |
|
|
|
|
|
